13F Holdings
中文EN

BHC Bausch Health Companies Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 885590 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.8%
TTM net income YoY-332.3%
TTM EPS YoY-332.0%
Revenue 3-yr CAGR9.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin11.2%
Net margin-7.6%
FCF margin16.8%
EBITDA margin21.6%

Returns

ROE—
ROA-3.2%
ROIC (approx.)5.5%
Asset turnover0.42x

Leverage & solvency

Liabilities / assets101.3%
Debt / equity—
Current ratio1.56x
Interest coverage0.78x

Cash quality & payout

Operating cash flow / net income-2.63x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue3.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$10.27B$9.62B$8.76B$8.12B$8.43B
R&D expense$629.00M$616.00M$604.00M$529.00M$465.00M
SG&A expense$3.44B$3.30B$2.92B$2.62B$2.62B
Operating income$1.81B$1.55B$963.00M$454.00M$450.00M
Interest expense$1.60B$1.39B$1.33B$1.46B$1.43B
Pretax income$367.00M$167.00M-$390.00M-$129.00M-$1.02B
Income tax$247.00M$239.00M$221.00M$83.00M-$87.00M
Net income$157.00M-$46.00M-$592.00M-$225.00M-$948.00M
EBITDA$3.02B$2.81B$2.23B$1.85B$2.00B
EPS (basic)0.42-0.13-1.62-0.62-2.64
EPS (diluted)0.42-0.13-1.62-0.62-2.64
Weighted avg. shares (diluted)375.00M368.00M364.90M362.00M358.90M
Balance sheet
Cash & equivalents$1.31B$1.20B$947.00M$591.00M$2.12B
Receivables$2.35B$2.14B$2.00B$1.79B$1.77B
Inventory$1.63B$1.59B$1.54B$1.09B$993.00M
Current assets$6.16B$5.77B$5.60B$4.25B$5.61B
PP&E, net$2.07B$1.78B$1.71B$1.60B$1.60B
Goodwill$11.27B$11.09B$11.18B$11.55B$12.46B
Intangibles$4.64B$5.55B$6.46B$5.80B$6.95B
Total assets$26.37B$26.52B$27.35B$25.69B$29.20B
Current liabilities$4.18B$6.75B$4.30B$3.94B$5.20B
Short-term debt$225.00M$2.67B$450.00M$432.00M$0
Long-term debt$20.59B$18.94B$21.94B$20.33B$22.65B
Total debt$20.82B$21.62B$22.39B$20.77B$22.65B
Total liabilities$25.99B$26.84B$27.43B$25.43B$29.24B
Shareholders' equity-$554.00M-$1.28B-$1.02B-$692.00M-$106.00M
Net debt$19.51B$20.41B$21.44B$20.18B$20.54B
Shares outstanding370.53M367.84M365.24M361.90M359.41M
Cash flow statement
Operating cash flow$1.40B$1.60B$1.03B-$728.00M$1.43B
Capital expenditure$397.00M$337.00M$215.00M$218.00M$269.00M
Free cash flow$1.00B$1.26B$817.00M-$946.00M$1.16B
Investing cash flow-$595.00M-$454.00M-$2.15B-$303.00M$409.00M
Financing cash flow-$742.00M-$868.00M$1.48B-$474.00M-$1.51B
Depreciation & amortization$1.21B$1.27B$1.26B$1.39B$1.55B
Stock-based compensation$216.00M$150.00M$132.00M$126.00M$128.00M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.